This trial is conducted in Europe. The aim of the trial is to investigate the postprandial glucose metabolism after treatment with faster-acting insulin aspart in subjects with type 1 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
42
Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
Novo Nordisk Investigational Site
Graz, Austria
Mean change in plasma glucose concentration
Time frame: From 0-1 hour after trial product administration
Rate of endogenous glucose production
Time frame: From 0-6 hours after trial product administration
Area under the serum insulin aspart concentration-time curve
Time frame: From 0-6 hours after trial product administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.